Evofem Biosciences, Inc. (EVFM)

Market Cap	3.40M
Revenue (ttm)	13.86M
Net Income (ttm)	-119.92M
Shares Out	121.22M
EPS (ttm)	-7.70
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	623,407
Open	0.0219
Previous Close	0.0219
Day's Range	0.0200 - 0.0220
52-Week Range	0.0130 - 5.5500
Beta	-1.21
Analysts	Buy
Price Target	1.84 (+9,100.0%)
Earnings Date	Mar 1, 2023

About EVFM

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Saundra Pelletier
• Employees: 119
• Stock Exchange: OTCMKTS
• Ticker Symbol: EVFM

Financial Performance

In 2021, EVFM's revenue was $8.24 million, an increase of 1748.43% compared to the previous year's $446,000. Losses were -$205.19 million, 44.2% more than in 2020.

Analyst Forecast

According to 7 analysts, the average rating for EVFM stock is "Buy." The 12-month stock price forecast is $1.84, which is an increase of 9,100.00% from the latest price.

Price Target

$1.84

(9,100.00% upside)

Analyst Consensus: Buy